← Browse by Condition
Medical Condition

pik3ca related overgrowth spectrum pros

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1, Phase 2
NCT06975618 Phase 1, Phase 2
Recruiting

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

Enrollment
141 pts
Location
China
Sponsor
Haihe Biopharma Co., Ltd.
View Trial →